Healthcare
Senzime AB (publ)(SNZZF)
Live Price
Offline$0.4785
+0.00% today
1Y Change
-7.13%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $740.00M
- Revenue Growth
- +77.4%
- EPS Growth
- +3.2%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Senzime AB (publ) (SNZZF) is a Healthcare stock with a market cap of $740.00M and listed on OTC. The stock last traded around $0.48 and down 7.1% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +77.4%, EPS growth of +3.2%, a dividend yield of 0.0%. What stands out right now is revenue +77.4%, EPS +3.2%, free cash flow +11.7% with operating margin -116.3% and ROIC -36.8%. Valuation sits in the middle of the pack at price/sales 7.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SNZZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+77.4% vs +7.6% peer median
Operating Margin
Below sector median
-116.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 22, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +77.4% and EPS at +3.2%, with operating margin around -116.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 22, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 18, 2026 | -125.0% | -4.9% | -13.4% | -19.2% |
2025 Sep 30, 2025 | -33.5% | +0.0% | +0.0% | -7.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNZZF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNZZF Max Drawdown
-38.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNZZF and SPY.
Company Overview
Senzime AB (publ)
Other OTC
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
- Leadership
- Philip Siberg
- IPO Date
- Jan 31, 2017
- Employees
- 54
- Street Address
- Ulls vAeg 41
- Mailing
- Uppsala, 756 51
- Region
- Uppsala, SE
- Reporting Currency
- USD
- Investor Line
- 46 18 51 56 40
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.2
- Price/Book
- 2.6
Growth
- Revenue
- +77.4%
- EPS
- +3.2%
- Free Cash Flow
- +11.7%
Profitability
- Gross Margin
- 31.0%
- Operating Margin
- -116.3%
- Net Margin
- -120.7%
- ROE
- -38.3%
- ROIC
- -36.8%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 3.76
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.